The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
Introduction: The safety of subcutaneous immunotherapy (SCIT), and particularly the dramatic issue of fatal reactions, has been an obstacle that limited the implementation of a therapy with unique characteristics of action on the causes of allergy. The introduction of sublingual immunotherapy (SLIT) was aimed at solving safety problems while maintaining clinical efficacy. Areas covered: For more than 20 years, SLIT has been based on allergen extracts in drops at low average doses.